Dry Eye Disease and DEWS II – Ophthalmology Management

Dry eye disease (DED) affects millions of patients worldwide and is a common reason to seek eye care. A variety of DED therapies are available, but because DED varies in severity between patients no single therapy works for everyone. Evaluation and management of DED relying on evidence-based medicine is the best approach.

This article addresses the following questions:

• What guidelines exist regarding treatment?
• What does Medicare say about treatment of DED?
• We understand use of amniotic membrane therapy is heavily audited. Where does it come into the plan?
• Do payers typically reject claims for treatments that don’t adhere strictly to the steps outlined in DEWS II?

This article was published in Ophthalmology Management’s Coding & Reimbursement column, which is written by Corcoran’s Senior Consultant and Co-Founder, Suzanne Corcoran, COE. To view the entire article in Ophthalmology Management, click on the link below:

https://www.ophthalmologymanagement.com/issues/2023/may-2023/coding-amp;-reimbursement